FinancialNewsletterPress releases

Q1 Interim Report July – September 2026

Hamlet Biopharma

|

November 12, 2026

Related Documents

HBP_Q1_INTERIM REPORT JULY – SEPTEMBER 2026.pdf

Recent posts

Press release – Lund, November 13th, 2026 – Hamlet BioPharma presented at Aktiespararna Life Science event on November 12th, 2026

November 13, 2026

Q1 Interim Report July – September 2026

November 13, 2026

Pressrelease – Lund, 10 November 2026 – Blåscancerbehandling med Alpha1H uppmärksammas i internationell vetenskaplig publikation

November 10, 2026

Pressrelease – Lund, November 10th, 2026 – Bladder cancer treatment with Alpha1H Highlighted in International Scientific Publication

November 10, 2026

Pressrelease – Lund, 10 November 2026 – Blåscancerbehandling med Alpha1H uppmärksammas i internationell vetenskaplig publikation

Press release – Lund, November 13th, 2026 – Hamlet BioPharma presented at Aktiespararna Life Science event on November 12th, 2026

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

© 2026

Hamlet BioPharma.